title: Cardioprotection by curcumin post-treatment in rats with established chronic kidney disease.
abstract: OBJECTIVE
  The pathogenic mechanisms leading to cardiovascular disorders in patients with chronic kidney disease have not been clearly established, although increased oxidative stress has been pointed out as a potential cause. Therefore, as cardiovascular events are still the first cause of death in patients with chronic kidney disease and traditional drugs or therapies rarely have effects on cardiac complications, we sought to determine the effect of curcumin in treating cardiac dysfunction in rats with established chronic renal disease.
  
  
  RESULTS
  Treatment consisted in daily administration of curcumin (120 mg/kg/day) dissolved in 0.05% carboxymethylcellulose via oral gavages during 30 days, beginning from day 30 after 5/6 nephrectomy (5/6Nx). Cardiac function, markers of oxidative stress, activation of PI3K/Akt/GSK3β and MEK1/2-ERK1/2 pathway, metalloproteinase-II (MMP-2) content, overall gelatinolytic activity, ROS production and mitochondrial integrity were evaluated after 1-month treatment. Curcumin restored systolic blood pressure, diminished interventricular and rear wall thickening, decreased left ventricle dimension at end-systole (LVSd) and restored ejection fraction in nephrectomized rats. Also, it diminished metalloproteinase-II levels and overall gelatinase activity, decreased oxidative stress and inhibited the mitochondrial permeability transition pore opening.
  
  
  CONCLUSIONS
  Our findings suggest that curcumin might have therapeutic potential in treatment of heart disease in patients with established CKD by attenuating oxidative stress-related events as cardiac remodeling, mitochondrial dysfunction and cell death.
authors.affiliation: Department of Cardiovascular Biomedicine, National Institute of Cardiology I. Ch, Juan Badiano No. 1. Colonia Sección XVI, México, 14080, DF, Mexico.
authors.forename: Sauri
authors.initials: S
authors.lastname: Hernández-Reséndiz
authors.forename: Francisco
authors.initials: F
authors.lastname: Correa
authors.forename: Wylly R
authors.initials: WR
authors.lastname: García-Niño
authors.forename: Mabel
authors.initials: M
authors.lastname: Buelna-Chontal
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Roldán
authors.forename: Ixchel
authors.initials: I
authors.lastname: Ramírez-Camacho
authors.forename: Carolina
authors.initials: C
authors.lastname: Delgado-Toral
authors.forename: Roxana
authors.initials: R
authors.lastname: Carbó
authors.forename: José
authors.initials: J
authors.lastname: Pedraza-Chaverrí
authors.forename: Edilia
authors.initials: E
authors.lastname: Tapia
authors.forename: Cecilia
authors.initials: C
authors.lastname: Zazueta
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002316:Cardiotonic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D003474:Curcumin / Q000494:pharmacology* / Q000627:therapeutic use*; D018093:Gelatinases / Q000378:metabolism; D006321:Heart / Q000187:drug effects*; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D033681:Mitochondrial Membrane Transport Proteins / Q000037:antagonists & inhibitors; D000083162:Mitochondrial Permeability Transition Pore; D009206:Myocardium / Q000378:metabolism; D009392:Nephrectomy; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013318:Stroke Volume / Q000187:drug effects; D020257:Ventricular Remodeling / Q000187:drug effects
chemical_list: D002316:Cardiotonic Agents; D033681:Mitochondrial Membrane Transport Proteins; D000083162:Mitochondrial Permeability Transition Pore; D017382:Reactive Oxygen Species; D018093:Gelatinases; D020778:Matrix Metalloproteinase 2; D003474:Curcumin